Compare Incyte Corporation (INCY) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Liberty Global Ltd Class C — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Liberty Global Ltd Class C trades at $10.14 (market cap $3.48B). The key difference: Incyte Corporation is far larger — about 7.1× Liberty Global Ltd Class C's market cap, and Incyte Corporation is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| INCY | LBTYK | |
|---|---|---|
Market Cap | $24.54B | $3.48B |
Sector | Health | Technology |
52-Week High | $129.93 | $12.67 |
52-Week Low | $81.61 | $9.59 |
Enterprise Value | $20.04B | $10.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
LBTYK trades at $10.13, up 1.4% on the day, amid a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses, while full-year 2025 showed a net loss of $7.14B despite $4.88B revenue. Positive cash flow trends and the upcoming Ziggo Group spin-off in 2027 are key developments, with analyst sentiment leaning bullish with 69% buy ratings.
The outlook hinges on execution of asset monetizations and the Ziggo listing, offering upside from a discounted valuation, but high losses and competitive pressures pose significant risks. Investors should weigh the sum-of-parts opportunity against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
